REVB Valuation

Revelation Biosciences Inc

Add to Watchlist

Advanced Chart

2.760

-0.03(-1.075%)1D

Overview
Forecast
Valuation
Earnings

REVB Relative Valuation

REVB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, REVB is overvalued; if below, it's undervalued.

Historical Valuation

Revelation Biosciences Inc (REVB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.66. The fair price of Revelation Biosciences Inc (REVB) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：2.80

Fair

-0.28

Trailing

Forward

0.00

EV/EBITDA

Revelation Biosciences Inc. (REVB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.04

EV/EBIT

Revelation Biosciences Inc. (REVB) has a current EV/EBIT of 0.04. The 5-year average EV/EBIT is -0.30. The thresholds are as follows: Strongly Undervalued below -4.63, Undervalued between -4.63 and -2.47, Fairly Valued between 1.86 and -2.47, Overvalued between 1.86 and 4.03, and Strongly Overvalued above 4.03. The current Forward EV/EBIT of 0.04 falls within the Historic Trend Line -Fairly Valued range.

0.00

Revelation Biosciences Inc. (REVB) has a current PS of 0.00. The 5-year average PS is 0.38. The thresholds are as follows: Strongly Undervalued below -2.90, Undervalued between -2.90 and -1.26, Fairly Valued between 2.01 and -1.26, Overvalued between 2.01 and 3.65, and Strongly Overvalued above 3.65. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Revelation Biosciences Inc. (REVB) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Revelation Biosciences Inc. (REVB) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Revelation Biosciences Inc (REVB) has a current Price-to-Book (P/B) ratio of 1.12. Compared to its 3-year average P/B ratio of 0.93 , the current P/B ratio is approximately 20.85% higher. Relative to its 5-year average P/B ratio of -142.18, the current P/B ratio is about -100.79% higher. Revelation Biosciences Inc (REVB) has a Forward Free Cash Flow (FCF) yield of approximately -381.86%. Compared to its 3-year average FCF yield of -415.21%, the current FCF yield is approximately -8.03% lower. Relative to its 5-year average FCF yield of -288.45% , the current FCF yield is about 32.38% lower.

1.11

P/B

Median3y

0.93

Median5y

-142.18

-373.65

FCF Yield

Median3y

-415.21

Median5y

-288.45

Competitors Valuation Multiple

The average P/S ratio for REVB's competitors is 4.49, providing a benchmark for relative valuation. Revelation Biosciences Inc Corp (REVB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

REVB.O

Revelation Biosciences Inc

Calidi Biotherapeutics Inc

Applied DNA Sciences Inc

Performance Decomposition

Market capitalization of REVB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of REVB in the past 1 year is driven by Unknown.